Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab with CHOP in Young Patients with Peripheral T-cell Lymphoma
NCT00646854Phase 3Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2008
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of alemtuzumab in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Event-Free Survival at 96 months. Started Jun 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00646854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646854.